MMP9 and neoplasm: The sequential delivery of CA4-NPs and MMP9-DOX-NPs increased tumor-selective drug release by amplifying MMP9 expression and enhanced antitumor efficacy with a tumor inhibition rate of 88.2% (Fig. 1B,C).